Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR

Perpetual Ltd purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,174 shares of the biotechnology company’s stock, valued at approximately $1,059,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Darwin Global Management Ltd. acquired a new stake in United Therapeutics during the third quarter worth about $317,617,000. Invesco Ltd. boosted its holdings in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the period. Balyasny Asset Management L.P. grew its stake in shares of United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after buying an additional 136,883 shares during the period. Finally, Sofinnova Investments Inc. acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $34,055,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $564.81 on Monday. The company has a market capitalization of $24.76 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $607.89. The firm has a 50 day moving average price of $506.70 and a 200 day moving average price of $479.77.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the prior year, the firm earned $6.19 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at $63,688.30. The trade was a 98.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00. The SEC filing for this sale provides additional information. Insiders sold 339,270 shares of company stock worth $171,740,110 in the last three months. 10.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on UTHR shares. Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. TD Cowen lifted their target price on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. UBS Group upped their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $586.00.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
• Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.